about
The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stressRole of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastomaYKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitisThe chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathwaysA YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancersPotential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cellsCirculating glioma biomarkersThe Role of CHI3L1 (Chitinase-3-Like-1) in the Pathogenesis of Infections in Burns in a Mouse ModelInhibitory activity of YKL-40 in mammary epithelial cell differentiation and polarization induced by lactogenic hormones: a role in mammary tissue involutionCrystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the diseaseHigh serum YKL-40 level after surgery for colorectal carcinoma is related to short survivalCarbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cellsSerum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor.Resveratrol represses YKL-40 expression in human glioma U87 cells.The immunologic homunculus in rheumatoid arthritis.Gene expression in papillary thyroid carcinoma reveals highly consistent profilesUtility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies.High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancerNoninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.Expression of the chitinase family glycoprotein YKL-40 in undifferentiated, differentiated and trans-differentiated mesenchymal stem cells.Specific targeting of gene expression to a subset of human trabecular meshwork cells using the chitinase 3-like 1 promoter.Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia.Establishment of a quantitative PCR system for discriminating chitinase-like proteins: catalytically inactive breast regression protein-39 and Ym1 are constitutive genes in mouse lungBreast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers.Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study.Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions.Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.Cancer risk by combined levels of YKL-40 and C-reactive protein in the general populationChitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer.Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analysesStabilin-1, a homeostatic scavenger receptor with multiple functions.Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancerIs YKL-40 a new therapeutic target in cancer?Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resectionSerum YKL-40 Levels in Patients with Gastric CancerYKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
P2860
Q24292760-38138D33-77F1-41E1-8E9D-A1B2C5245C5CQ24295370-B68BECA8-9BBA-4FC9-957D-226161D2A3CBQ24531928-39D79DB7-8B0C-480C-BB46-90549415A901Q24534189-3E6C0C43-3ACB-4CBA-A268-59AB8A198B95Q24595527-80AF5159-A965-4E8A-BDA4-76CC55D3E09FQ24656942-CE2EBD94-A982-4B60-8ECC-ECF1EA31A7FAQ26830329-D4F926BF-AA5D-41A1-8542-839B076514F5Q27313397-7321FCDC-7B32-4932-BF16-73EFB0E945E8Q27317208-03156E0D-D3AB-4976-8C87-3E6545741EE4Q27641650-57DEFEDB-FDD8-43AC-81E6-01A0D954C37CQ28205002-3AB87EB1-2AE3-4514-B667-80603B57E228Q28215091-568B6967-DB9B-4828-923C-83A378972981Q28586972-2F0D3BEF-AB16-4070-B877-19932677908FQ33255102-76A66DA0-B94C-45B0-8F21-2AD640C94013Q33343967-92A8E6E5-C852-4BF2-BC7C-D0A751342562Q33732189-EEA80CFF-CE8A-4D44-A3FD-8DDE174C8A7BQ33806414-6356F8E7-1F34-4818-9C2D-4B25DC031923Q33952877-4F586F36-9ACC-4513-8341-F4D68B5EC9C4Q34494109-B4219898-4B80-4DA0-96EC-8C88903DD671Q34507263-5C8619D1-83F3-4ABE-AF72-C36EC587FB3AQ34605692-A9E18E2A-7F7D-4391-A3C5-21095624274DQ34720622-4E50DB5E-429A-45B9-83ED-373023D042ACQ35153678-9E4D5B42-634D-45A7-A645-80020AE661B9Q35168063-194906B4-E58A-44D9-AC32-818A22498211Q35311500-41080418-9816-4BFA-8061-209086BAC976Q35527112-8D42029F-4BCB-464B-84EB-066D5E417AF5Q35548928-14A9798B-38F3-467F-B120-F009986E1374Q35549462-BC4DD957-6722-4794-9204-842A0C5F5FDDQ35647254-71EC9471-AE33-41A5-9355-56797318486FQ35653750-6BDD70C1-32AA-46B3-A8EF-0CE65EC9E522Q35791353-49E63027-3312-4709-8A35-751A11B3889AQ35791398-A4BE9F80-AB53-412F-9AE4-5733515FC87FQ36600426-945B55AB-0FB6-447A-9F89-47EE512E3D70Q36622094-8428250D-4FE1-49C9-B3A3-C74874FFE9FCQ36709555-C0BC2A0A-1836-42BB-9406-C87639A4C542Q37166698-ECA738BF-22C0-46D1-8735-A2EFB3181E91Q37218917-A07FBB8D-83E6-4884-9BD7-4C86A8A5B7CBQ37334247-1058E8D9-A449-4396-90F7-64F746413A26Q37486590-A0B3FAE0-AE05-43A9-B9AE-3AF7074C3AA6Q37548804-A77C4A1D-4E9D-454C-B6AC-CAE3D188F984
P2860
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Serum YKL-40 and colorectal cancer.
@ast
Serum YKL-40 and colorectal cancer.
@en
type
label
Serum YKL-40 and colorectal cancer.
@ast
Serum YKL-40 and colorectal cancer.
@en
prefLabel
Serum YKL-40 and colorectal cancer.
@ast
Serum YKL-40 and colorectal cancer.
@en
P2093
P2860
P356
P1476
Serum YKL-40 and colorectal cancer
@en
P2093
I J Christensen
J S Johansen
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690238
P407
P577
1999-03-01T00:00:00Z